Andere Sprachen Lobe Sciences Ltd.

Aktien

Markt geschlossen - Canadian Securities Exchange Andere Börsenplätze 15:30:00 24.05.2024			% 5 Tage	% 1. Jan.
0.015 ^CAD	-25.00%		-25.00%	-40.00%

30.04.	Lobe Sciences Ltd. meldet Ergebnis für das zweite Quartal und die sechs Monate bis zum 29. Februar 2024	CI
15.02.	Lobe Sciences Ltd. meldet Ergebnis für das am 31. August 2023 endende Geschäftsjahr	CI

Lobe Sciences Ltd. and Clearway Global Announce Change of Control and Focus on Creating Value for Shareholders	21.05.
Lobe Sciences Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended February 29, 2024	30.04.
Lobe Sciences Ltd. Reports Earnings Results for the Full Year Ended August 31, 2023	15.02.
Lobe Sciences Provides Company Review of 2023	08.01.
Lobe Sciences Provides Update on L-130 Clinical Program	07.12.
Lobe Sciences Provides Update on L-130 Clinical Program	07.12.
Lobe Sciences Ltd. Provides Update on L-130 Clinical Program	07.12.
Lobe Sciences Provides Update on L-130 Oral Psilocin Compound	05.12.
Lobe Sciences Provides Update on L-130 Oral Psilocin Compound	05.12.
Lobe Sciences : Corporate Presentation	11.10.23
Lobe Sciences : Corporate Presentation Q3, 2023	09.10.23
Lobe Sciences Appoints CFO	18.09.23
Lobe Sciences Ltd. Appoints Mathew Lee as Chief Financial Officer	18.09.23
Lobe Sciences Amends Terms of Altemia Share Purchase Agreement	15.09.23
Lobe Sciences, Ltd. Announces Amendment to the Acquisition of Altemia™ & Company	15.09.23
Lobe Sciences Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended May 31, 2023	01.08.23
Lobe Sciences Initiates Phase 1 Clinical Trial of L-130	27.06.23
Lobe Sciences Ltd. Initiates Phase 1 Clinical Trial of L-130	27.06.23
Lobe Sciences Appoints Baxter Phillips III, MBA as Chief Operating Officer	07.06.23
Lobe Sciences Appoints Baxter Phillips as Chief Operating Officer	07.06.23

Keine Ergebnisse zu dieser Suche